Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Qiagen NV QGEN

Technology Scientific & Technical Instruments
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic... see more

Recent & Breaking News (NYSE:QGEN)

QIAGEN MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Qiagen N.V. is Fair to Shareholders; Investors are Encouraged to Contact the Firm - QGEN

GlobeNewswire March 3, 2020

Thermo Fisher Scientific to Acquire QIAGEN N.V.

PR Newswire March 3, 2020

QIAGEN Announces 20-F Annual Report Filing for 2019 Results

Business Wire March 2, 2020

QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2

Business Wire February 26, 2020

QIAGEN's QuantiFERON®-TB Gold Plus to be Adopted for Latent TB Testing in Nigeria

Business Wire February 19, 2020

QIAGEN Reports Results for Fourth Quarter and Full-Year 2019

Business Wire February 4, 2020

QIAGEN Launches FFPE and Liquid Biopsy PIK3CA Diagnostics in Europe to Enhance Precision Medicine in Advanced Breast Cancer

Business Wire February 3, 2020

QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer

Business Wire January 13, 2020

QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results

Business Wire January 10, 2020

QIAGEN Celebrates Surpassing 2,500 Cumulative Placements of QIAsymphony

Business Wire January 9, 2020

Calibre Scientific Acquires NeXtal Biotechnologies to Further Expand its Protein Portfolio

GlobeNewswire January 8, 2020

QIAGEN Concludes Strategic Alternatives Review; Decides to Focus on Stand-Alone Business Strategy to Drive Future Value Creation

Business Wire December 24, 2019

QIAGEN and DiaSorin Receive FDA Approval for The LIAISON QuantiFERON-TB Gold Plus Test on LIAISON Platforms and Begin Commercial Launch

Business Wire November 27, 2019

ROSEN, A GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against QIAGEN N.V. - QGEN

GlobeNewswire November 25, 2019

QIAGEN and LabCorp deepen relationship with widespread use of bioinformatics solutions

Business Wire November 20, 2019

QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives

Business Wire November 15, 2019

QIAGEN receives several conditional, non-binding indications of interest, and decides to enter into discussions to explore potential strategic alterna-tives

Accesswire November 15, 2019

QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives

Business Wire November 15, 2019

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Qiagen (QGEN) Investors with Significant Losses to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud

GlobeNewswire November 13, 2019

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of QIAGEN N.V.

GlobeNewswire November 12, 2019